Rouen

• PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended recruitment
  2024-510704-37-00 5 2017-03-22 ER+/HER2- metastatic breast cancer
• A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL … Ended recruitment
  2024-515846-18-00 7 2016-09-19 Newly diagnosed Diffuse Large B Cell Lymphoma
• PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient … Ended recruitment
  2024-518741-21-00 4 2014-12-23 colon cancer
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Ended recruitment
  2024-516996-34-00 5 2012-04-12 oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
• Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended recruitment
  2024-515171-35-00 5 2011-07-06 Prostatic adenocarnicoma with high risk of recurrence
• Treatment protocol for osteosarcomas in children, adolescents and adults including a randomized trial and biological studies Ended recruitment
  2024-514756-32-00 5 2007-03-19 High grade osteosarcoma
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac … Ended
  2023-508959-39-00 5 2025-02-20 Moderate to Severe Plaque Psoriasis
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 Relapsed or Refractory High-Risk Myelodysplastic Syndrome
• Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien … Ended
  2022-502584-38-00 5 2023-12-12 Locally advanced squamous cell carcinoma of the head and neck
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• A Study of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with R/R PTCL Ended
  2022-500391-62-00 9 2023-01-19 Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL
• A Phase 2 Study of Sotatercept for Combined Postcapillary and Precapillary Pulmonary Hypertension Treatment Ended
  2023-509141-12-00 4 2022-04-28 Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH
• Isatuximab in type I cryoglobulinemia: A prospective pilot study ICE STUDY Ended
  2024-515039-31-00 4 2022-02-10 Isatuximab in type I cryoglobulinaemia: A prospective pilot study
• Short-term effectiveness of Gabapentin versus Placebo in acute Lumbosacral Radiculalgia by herniation disc: a prospective, multicentric, ran … Ended
  2024-518053-42-00 6 2022-02-09 lumbosacral radiculalgia
• Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Ended
  2022-501615-14-00 4 2021-11-08 Classical Hodgkin Lymphoma
• Re-purposing of 2 well-known molecules (ketamine and magnesium sulfate) to treat a specific and excruciating type of pain (chronic cluster h … Ended
  2024-518943-38-00 5 2021-09-15 refractory chronic cluster headache
• ASTX727 AND DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN VERY HIGH RISK MDS OR AML PATIENTS Ended
  2024-515353-24-00 4 2021-06-22 Patients with high risk myelodysplastic syndrome or acute myeloid leuk
• Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended
  2022-500820-31-00 4 2020-07-16 Recurrent or metastatic squamous cell carcinoma of the head and neck
• Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip … Ended
  2022-500418-24-00 10 2020-01-17 Locally Recurrent Inoperable or Metastatic Triple Negative Breast Canc
• Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer Ended
  2023-503831-17-00 4 2019-12-23 The treatment of participants with HRRm and/or HRD-positive cancer
• A Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) … Ended
  2024-512537-33-00 5 2019-11-28 Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
• MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study Ended
  2024-514873-22-00 5 2019-10-16 Unresectable locally advanced and/or metastatic soft-tissue sarcoma
• Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1 Ended
  2024-511885-35-00 5 2019-07-03 macular telangiectasia type 1
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok

Showing 145–168 of 175 trials